SEC Form 4 Reporting Owner · CIK 0001788393
Kamal Adawi
CFO at Fate Therapeutics Inc · CFO at Exagen Inc
Bought (12 mo)
—
Sold (12 mo)
—
Form 4 Filings
11
Companies
2
Filing Activity
2026-01-16
first filed 2021-02-25
Trading record
Open-market buys
—
0 filings
Open-market sales
−$61.6K
4 filings
Sales under a 10b5-1 plan
0%
0 of 4 sale filings · 2 undisclosed
Companies
| Company | Role | Filings | Bought | Sold | Net | Holding after latest filing |
|---|---|---|---|---|---|---|
| FATEFate Therapeutics Insider trading | CFO | 2 | — | — | — | 100,000 2026-01-16 |
| XGNExagen Insider trading | CFO | 9 | — | 29,010 | −29,010 | 243,749 2024-03-06 |
Common-stock shares bought and sold on the open market, as reported on Form 4. The holding is what the latest filing at each company reported owning after its transactions.